Page 2 - Pardes Bioscience News Today

CARLSBAD, Calif., Aug. 15, 2022 -- Pardes Biosciences, Inc. , a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel oral antiviral drug candidate for the treatment and... | August 15, 2022

Equities research analysts predict that Pardes Biosciences, Inc. (NASDAQ:PRDS – Get Rating) will announce earnings of ($0.39) per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Pardes Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.40) and the highest estimate coming in at ($0.38). The company […]

Wall Street analysts predict that Pardes Biosciences, Inc. (NASDAQ:PRDS – Get Rating) will post earnings per share of ($0.25) for the current quarter, Zacks reports. Zero analysts have made estimates for Pardes Biosciences’ earnings. The highest EPS estimate is ($0.23) and the lowest is ($0.27). The company is expected to issue its next earnings report […]

Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.

Pardes Biosciences Inc (NASDAQ:PRDS – Get Rating) – Equities researchers at SVB Leerink lowered their FY2023 EPS estimates for Pardes Biosciences in a report issued on Wednesday, March 30th. SVB Leerink analyst R. Ruiz now anticipates that the company will post earnings per share of $7.00 for the year, down from their prior estimate of […]

Mr. Wiggans brings over 40 years of biopharmaceutical industry experience, including over 25 years in chief executive leadership roles with multiple...

02.03.2022 - Mr. Wiggans brings over 40 years of biopharmaceutical industry experience, including over 25 years in chief executive leadership roles with multiple successful acquisitions. His expertise will be beneficial to Pardes as the company rapidly ... Seite 1

The Carlsbad startup is in early clinical trials for an experimental antiviral oral treatment for COVID-19, akin to Tamiflu for influenza.

Startup is in early clinical trials for an experimental antiviral oral treatment for COVID-19, akin to Tamiflu for influenza.